论文部分内容阅读
本文报告采用舒肝健脾、活血化瘀、软坚散结中药肝康冲剂配合肝动脉导管介入治疗原发性肝癌34例,并与单纯肝动脉导管治疗原发性肝癌31例进行了对照观察。结果显示:单纯化疗组、中西医结合组部分缓解率(PR)分别为6.5％(2/31)、11.8％(4/34),稳定率为41.9％(13/31)、50％(17/34),中西医结合组优于单纯化疗组(P>0.05)。平均生存期、中位生存期两组分别为7.32、6个月;8.72、7.5个月,中西医结合组比化疗拉有所延长。此外,中西医结合组在改善患者的临床证侯、提高带瘤机体免疫功能等方面也明显优于单纯化疗组。提示联合用药不但可以提高对局部癌灶的抑制率,减轻化疗药物的毒副作用,而且改善肝功能,提高机体的免疫功能,延长生存期。
This paper reports 34 cases of primary liver cancer treated with Shugan Jianpi, Huoxuehuayu, Ruanjian Sanjie Chinese medicine Gankang Granules combined with hepatic artery catheterization, and 31 cases with primary hepatic artery catheter treatment of primary liver cancer. The results showed that the partial remission rate (PR) of the chemotherapy alone group and the integrated traditional Chinese and western medicine group was 6.5% (2/31), 11.8% (4/34), and the stability rate was 41.9% (13/31) and 50% (17). /34), the combination of traditional Chinese and Western medicine was superior to chemotherapy alone (P>0.05). The average survival time and median survival time were 7.32 and 6 months, respectively. At the age of 8.72 and 7.5 months, the TCM-WM group had a longer extension than chemotherapy. In addition, the integrated traditional Chinese and western medicine group was also superior to the chemotherapy alone group in improving clinical syndromes and improving the immune function of tumor-bearing patients. It is suggested that the combined use of drugs can not only increase the inhibition rate of local cancer, reduce the toxic and side effects of chemotherapy drugs, but also improve liver function, improve the body’s immune function, and prolong the survival period.